Mechanisms of leukocyte regulation by complement-derived factors.
Progress over the past five years has drawn attention to the fact that the anaplylatoxins are important factors in both leukocyte activation and regulation events. The C5 anaphylatoxin has been proposed to play major role in leukocyte aggregation and adherence phenomenon. Influences of C5a on the leukocyte may lead to clinical manifestations such as respiratory distress syndrome after trauma or postpump syndrome after cardiopulmonary bypass, both effects derived from leukocyte sequestration. Many other clinical conditions involving repeated transient sequestration of leukocytes, particularly in the pulmonary vasculature, may eventually be recognized as a complication of systemic complement activation. Dramatic pathologic changes observed in the lungs of animals exposed to either C3a or C5a emphasizes the potential damage that these factors may exert via cellular activation mechanisms (Huey et al., 1983). More recent evidence that the anaphylatoxins are potent immunoregulatory factors under in vitro conditions suggests a physiologic role for these humoral factors in nonspecific modulation of the immune response. It is an attractive hypothesis to suggest that once activated, complement is capable of relaying information to the cellular immune system via the anaphylatoxins. Other components of the complement system have long been known to exert regulatory influences on the immune system, and perhaps molecular description of such entities as the C3d-K fragment will serve to unravel this seemingly more complex effector system. In any case, as our understanding of both the chemical and biologic nature of factors derived from blood complement components advances, it has become apparent that a major function of complement may be to modulate the immune response. We have already demonstrated that these factors are selective both for cell type and for eliciting a variety of cellular responses. From this, one can infer that manipulation of the cellular events will eventually be possible. Hence a therapeutic value may be realized once involvement of these complement factors under in vivo conditions is better characterized.
D000706:Anaphylatoxins / Q000502:physiology*; D000917:Antibody Formation; D002449:Cell Aggregation; D002634:Chemotaxis, Leukocyte; D002999:Clone Cells / Q000276:immunology; D003176:Complement C3 / Q000502:physiology; D015926:Complement C3a; D015933:Complement C3d; D003182:Complement C5 / Q000502:physiology; D015936:Complement C5a; D007111:Immunity, Cellular; D007962:Leukocytes / Q000502:physiology*; D008213:Lymphocyte Activation; D010455:Peptides / Q000502:physiology*; D011951:Receptors, Complement / Q000502:physiology*
D000706:Anaphylatoxins; D003176:Complement C3; D003182:Complement C5; D010455:Peptides; D011951:Receptors, Complement; D015926:Complement C3a; D015933:Complement C3d; D015936:Complement C5a